, , , , , ,


From the Rutgers Cancer Institute of New Jersey:

The director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey, Janice M. Mehnert, MD, is a co-principal investigator on a $2,271,427 grant (R01CA193970-01A1) recently awarded by the National Cancer Institute (NCI).  She is collaborating with researcher Ryan J. Sullivan, MD, at Massachusetts General Hospital Cancer Center to improve upon available cancer therapies that aim to block specific pathways that promote tumor growth.

When compared to chemotherapy, anti-cancer therapies designed to block the BRAF and MEK pathways that are known for promoting tumor growth improve response rate, progression free survival and overall survival in more than 50 percent of patients with BRAF-mutant melanoma that has spread to other parts of the body. While these drugs have become standards of care, patients still experience disease progression and die of their disease.  Drs. Mehnert and Sullivan and colleagues aim to improve the effectiveness of BRAF-directed therapy by targeting the death of cancer cells.
Read more here.